Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)

Next Previous
X
Search
Trial Profile

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Registrational
  • Acronyms RAMSES follow-on; RAMSES OLE
  • Sponsors Aimmune Therapeutics

    • Most Recent Events

    • 30 Jun 2022 Results presented in the Aimmune Therapeutics Media Release.
    • 30 Jun 2022 According to an Aimmune Therapeutics media release, results from an analysis to be presented on health-related quality of life (HRQoL) among patients from the Phase 3 PALISADE, ARC004 (PALISADE follow-on), ARTEMIS, RAMSES and ARC011 (RAMSES follow-on) trials will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress.
    • 16 Feb 2022 Results published in an Aimmune Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top